The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension — TRIMETA-PH  

Precapillary Pulmonary Hypertension Clinical Trial

Official title: The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension Patients in National Cardiovascular Center Harapan Kita Hospital Indonesia

Status Completed

Clinical Trial Summary

The study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.

Clinical Trial Description

Right ventricular dysfunction is the worst mortality predictor in pulmonary arterial hypertension (PAH). Recent study has described that approximately 25% of PAH patients will developed into right ventricular failure despite therapeutic reduction of pulmonary vascular resistance. Subsequently, several studies have shown that fatty acid accumulation in right ventricle was inversely correlated with right ventricular function in PAH patients. Several PAH animal studies have revealed that metabolic glucose oxidation impairment through increased aerobic glycolysis, mitochondrial dysfunction, and lipotoxicity play significant role in right ventricular failure. Moreover, several pulmonary hypertension animal studies have demonstrated the benefit of partial fatty acid inhibitor such as trimetazidine on right ventricle function. It was hypothesize that trimetazidine improved right ventricular function through indirect effect of increased glucose oxidation by blocking the Randle cycle. Therefore, we hypothesize that trimetazidine can improve right ventricular function in pulmonary arterial hypertension patients. ;

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Precapillary Pulmonary Hypertension

• NCT number: NCT03273387
• Study type: Interventional
• Source: Indonesia University
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: September 10, 2017
• Completion date: December 14, 2018